Mounting epidemiological studies confirmed that TNF-α blockade, which includes the use of adalimumab (specific monoclonal antibodies) and etanercept (Fc fusion protein) improves MetS components (waist circumference, and serum lipid and glycaemic metabolism), and subsequently decreases the risk of T2DM and CVD in various inflammatory diseases such as psoriasis or rheumatoid arthritis (RA) [72–74]. This evidence concerns the gene TNF and rheumatoid arthritis.